Low body weight and type of protease inhibitor predict discontinuation and treatment‐limiting adverse drug reactions among HIV‐infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort

Ole Kirk, Jens Lundgren, C. Pedersen et al.|HIV Medicine|2001

Cited by 17